February 3, 2023 6:45 am ET. KEYTRUDA plus chemotherapy significantly improved PFS versus standard of care chemotherapy alone as first-line treatment for patients with stage III-IV or recurrent endometrial carcinoma regardless of mismatch repair status.
See Original Article